Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: GlobeNewswire
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 4:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella Therapeutics Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing a
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) was given a new $145.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $143.00 price target on the stock, up previously from $92.00.MarketBeat
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 11/21/25 - Form 4
- 11/19/25 - Form 144
- 11/14/25 - Form SCHEDULE
- PVLA's page on the SEC website